Cited 14 times in
Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2022-11-24T00:42:18Z | - |
dc.date.available | 2022-11-24T00:42:18Z | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 0268-3369 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190919 | - |
dc.description.abstract | The clinical outcome of advanced-stage Extranodal NK/T cell lymphoma (ENKTL) patients using conventional chemotherapy is extremely poor. The aim of this study was to investigate the outcomes of advanced-stage ENKTL patients treated with non-anthracycline-based chemotherapy followed by upfront autologous stem cell transplant (ASCT). From 8 institutions, 27 patients were recruited from February 2016 to May 2019. Patients were treated with 4 cycles of VIDL induction chemotherapy. Patients who achieved complete response (CR) or partial response (PR) underwent upfront ASCT. This study is registered with clinicaltrial.gov, # NCT02544425. Twenty patients (74.1%) completed 4 cycles of VIDL induction. The overall response rate of VIDL was 74.1%, including 17 (63.0%) with CR and 3 (11.1%) with PR. Primary toxicity of the induction regimen was grade 3 or 4 neutropenia, and no treatment-related mortality was reported. Seventeen patients proceeded with upfront ASCT, and 9 patients relapsed after ASCT, among whom, 4 was central nervous system (CNS) relapse. The median duration of response was 15.2 months (95% CI, 6.3-24.1 months). This study suggested that VIDL induction chemotherapy followed by upfront ASCT is feasible and effective for the treatment of advanced-stage ENKTL. However, CNS relapse prevention is needed in the treatment of advanced-stage ENKTL. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.isPartOf | BONE MARROW TRANSPLANTATION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Hematopoietic Stem Cell Transplantation* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Induction Chemotherapy | - |
dc.subject.MESH | Lymphoma, Extranodal NK-T-Cell* / therapy | - |
dc.subject.MESH | Neoplasm Recurrence, Local | - |
dc.subject.MESH | Stem Cell Transplantation | - |
dc.subject.MESH | Transplantation, Autologous | - |
dc.title | Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Ga-Young Song | - |
dc.contributor.googleauthor | Dok Hyun Yoon | - |
dc.contributor.googleauthor | Cheolwon Suh | - |
dc.contributor.googleauthor | Joon Ho Moon | - |
dc.contributor.googleauthor | Dong Won Baek | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Gyeong-Won Lee | - |
dc.contributor.googleauthor | Jun Ho Yi | - |
dc.contributor.googleauthor | Yong Park | - |
dc.contributor.googleauthor | Ki Sun Jung | - |
dc.contributor.googleauthor | Seok Jin Kim | - |
dc.contributor.googleauthor | Deok-Hwan Yang | - |
dc.contributor.googleauthor | Won Seog Kim | - |
dc.identifier.doi | 10.1038/s41409-020-01160-2 | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J00383 | - |
dc.identifier.eissn | 1476-5365 | - |
dc.identifier.pmid | 33277620 | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.citation.volume | 56 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1205 | - |
dc.citation.endPage | 1208 | - |
dc.identifier.bibliographicCitation | BONE MARROW TRANSPLANTATION, Vol.56(5) : 1205-1208, 2021-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.